Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors.
Siegall will serve as CEO, president and chairman of the board of directors of the merged company, which will be called Immunome and will be headquartered in Seattle.
